Kolexia
Ravaud Alain Oncologie médicale
Ravaud Alain
Oncologie médicale
Hôpital Saint-André
Bordeaux, France
411 Activités
281 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinomes Néphrocarcinome Tumeurs du rein Métastase tumorale Tumeurs de la vessie urinaire Tumeurs du poumon Tumeurs de la prostate Récidive tumorale locale Carcinome transitionnel

Collaborateurs

Voir plus
Gross-Goupil Marine
Gross-Goupil Marine
Hôpital Saint-André, Bordeaux, France
Escudier Bernard
Escudier Bernard
Gustave-Roussy, Villejuif, France
Bernhard Jean-Christophe
Bernhard Jean-Christophe
Hôpital Pellegrin, Bordeaux, France
Oudard Stephane
Oudard Stephane
Hôpital Européen Georges Pompidou, Paris, France

Industries

Voir plus
Ipsen
18 collaboration(s)
Dernière en 2023
Pfizer
17 collaboration(s)
Dernière en 2023
BMS
10 collaboration(s)
Dernière en 2021
Merck-Serono
9 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
BISCAY: An Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Multi-Centre, Multi-arm Phase 1b Study in Patients With Muscle Invasive Bladder Cancer (MIBC) Who Have Progressed on Prior Treatment (BISCAY).
Essai Clinique (AstraZeneca)   11 mars 2024
Study of DF1001 in Patients With Advanced Solid Tumors: A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications
Essai Clinique (Dragonfly Therapeutics)   25 janvier 2024
Study to Assess Osimertinib in Patients w/ Adv Solid Tumours & Normal Kidney Function or Severe Kidney Impairment: Open-label,Non-randomised,Multicentre,Phase I Study to Assess the Pharmacokinetics, Safety & Tolerability of Osimertinib Following a Single Oral 80mg Dose to Patients w/ Adv Solid Tumours & Normal Renal Function or Severe Renal Impairment.
Essai Clinique (AstraZeneca)   24 novembre 2023
Clinical and Biological Differences between Upper Tract Carcinoma and Bladder Urothelial Cancer, Including Implications for Clinical Practice.
Cancers   23 novembre 2023
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214): A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Ipilimumab Versus Sunitinib Monotherapy in Subjects With Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma
Essai Clinique (BMS)   13 novembre 2023
Comprehensive analyses of immune tumor microenvironment in papillary renal cell carcinoma.
Journal for immunotherapy of cancer   09 novembre 2023
Néphrectomie totale élargie et thrombectomie cave robot assistée après immunothérapie
117e congrès français d'urologie   01 novembre 2023
2393P Ephrin signalling mediates resistance to programmed death ligand 1 (PD-L1) inhibition in urothelial carcinoma (UC)
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
2374P A phase Ib single-arm trial of bintrafusp alfa (BA) for pretreated, locally advanced/unresectable or metastatic (advanced) urothelial cancer (aUC)
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
1906P Metastasized non-clear cell renal cell carcinoma: Which entities are dangerous? Results learned from reference pathology of the SuniForecast study
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023